Table 2.
IHC results of primary tumor and metastases samples between responder and non-responder mRCC patients.
| Parameter (Cut-Off) |
Responders N (%) |
Non-Responders N (%) |
OR (95% CI) |
p-Value |
|---|---|---|---|---|
| Histology | ||||
| ccRCC | 34 (61.8) | 52 (85.3) | 3.57 (1.46–8.71) | 0.005 |
| Other | 21 (38.2) | 9 (14.7) | 1.00 (ref.) | |
| Grading | ||||
| 1–2 | 17 (48.6) | 10 (19.6) | 1.00 (ref.) | |
| 3 | 12 (34.3) | 26 (51.0) | 3.68 (1.30–10.40) | 0.014 |
| 4 | 6 (17.1) | 15 (29.4) | 4.25 (1.25–14.50) | 0.021 |
| CD3+ IC | ||||
| Median (IQR) | 90 (34–200) | 45 (25–210) | - | 0.77 |
| <40 | 15 (27.3) | 27 (44.3) | 1.00 (ref.) | 0.059 |
| ≥40 | 40 (72.7) | 34 (55.7) | 0.47 (0.22–1.03) | |
| CD8+ IC | ||||
| Median (IQR) | 100 (25–150) | 105 (25–139) | - | 0.76 |
| CD4+ IC | ||||
| Median (IQR) | 45 (12–70) | 60 (15–88) | - | 0.22 |
| <70 | 41 (74.6) | 32 (52.5) | 1.00 (ref.) | 0.015 |
| ≥70 | 14 (25.5) | 29 (47.5) | 2.65 (1.21–5.83) | |
|
CD8+/CD4+ ratio Median, IQR |
1.74 (0.54–3.71) | 1.20 (0.32–2.39) | - | 0.084 |
| Peri/intra-tumoral T cells | ||||
| Absent | 24 (43.6) | 26 (42.6) | 1.00 (ref.) | 0.91 |
| Present | 31 (56.4) | 35 (57.4) | 1.04 (0.50–2.18) | |
| CD56 TC | ||||
| Median (IQR) | 0 (0–40) | 0 (0–10) | - | 0.23 |
| <40 | 40 (72.7) | 54 (88.5) | 1.00 (ref.) | 0.035 |
| ≥40 | 15 (27.3) | 7 (11.5) | 0.35 (0.13–0.93) | |
| CD15 TC | ||||
| Median (IQR) | 1 (0–10) | 1 (0–5) | - | 0.70 |
| <30 | 48 (87.3) | 48 (78.7) | 1.00 (ref.) | 0.23 |
| ≥30 | 7 (12.7) | 13 (21.3) | 1.86 (0.68–5.06) | |
| CD68 TC | ||||
| Median (IQR) | 0 (0–40) | 0 (0–10) | - | 0.77 |
| ph-mTOR TC | ||||
| Median (IQR) | 20 (10–70) | 15 (0–70) | - | 0.25 |
| <15 | 16 (29.1) | 30 (49.2) | 1.00 (ref.) | 0.029 |
| ≥15 | 39 (70.9) | 31 (50.8) | 0.42 (0.20–0.91) | |
| PD-L1 TC/IC | ||||
| Median (IQR) | 3 (0–10) | 0 (0–5) | - | 0.46 |
| <10 | 40 (72.7) | 51 (83.6) | 1.00 (ref.) | 0.16 |
| ≥10 | 15 (27.3) | 10 (16.4) | 0.52 (0.21–1.29) |
N—number of patients, OR—odds ratio, CI—confidence interval, ccRCC—clear cell renal cell carcinoma, ref.—reference, IQR—interquartile range, TC—tumor cell, and IC—immune cell.